血液和骨髓移植临床研究网络试验 1102 开启高危骨髓增生异常综合征造血细胞移植的新纪元：实施中的挑战与机遇。
Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation.
机构信息
Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Rush University Medical Center, Chicago, Illinois.
出版信息
Cancer. 2021 Dec 1;127(23):4339-4347. doi: 10.1002/cncr.33826. Epub 2021 Aug 10.
Abstract
People who have advanced myelodysplastic syndromes (MDS) may live longer if they get a bone marrow transplant (BMT) instead of other therapies. However, only 15% of people with MDS actually get BMT. Experts say community physicians and transplant physicians should team up with insurance companies and patient advocacy groups to 1) spread this news about lifesaving advances in BMT, 2) ensure that everyone can afford health care, 3) provide emotional support for patients and families, 4) help patients and families get transportation and housing if they need to travel for transplant, and 5) improve care for people of under-represented racial and ethnic backgrounds.
摘要
对于患有骨髓增生异常综合征（MDS）的人来说，如果他们进行骨髓移植（BMT）而不是其他治疗，可能会活得更久。然而，实际上只有 15%的 MDS 患者接受了 BMT。专家表示，社区医生和移植医生应该与保险公司和患者权益组织合作，1）传播关于 BMT 中挽救生命的进展的消息，2）确保每个人都能负担得起医疗保健，3）为患者和家属提供情感支持，4）帮助患者和家属在需要进行移植时获得交通和住房，以及 5）改善代表性不足的种族和族裔背景的人的护理。
相似文献
1
Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation.血液和骨髓移植临床研究网络试验 1102 开启高危骨髓增生异常综合征造血细胞移植的新纪元：实施中的挑战与机遇。
Cancer. 2021 Dec 1;127(23):4339-4347. doi: 10.1002/cncr.33826. Epub 2021 Aug 10.
2
Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.异基因干细胞移植治疗成人骨髓增生异常综合征：移植前疾病负担的重要性。
Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.
3
[Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].[减低强度预处理异基因造血干细胞移植治疗骨髓增生异常综合征的研究进展 - 综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):969-74.
4
Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?哪些骨髓增生异常综合征患者应接受异基因干细胞移植，以及我们应该何时进行移植？
Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S43-9. doi: 10.1016/j.clml.2015.04.002.
5
Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older.异基因造血细胞移植对70岁及以上骨髓增生异常综合征患者是一种安全有效的治疗方法。
Biol Blood Marrow Transplant. 2017 Jan;23(1):1-2. doi: 10.1016/j.bbmt.2016.11.013. Epub 2016 Nov 16.
6
The Art of Transplantation: Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation.移植艺术：异基因造血干细胞移植的预处理强度。
Biol Blood Marrow Transplant. 2019 Mar;25(3):e71-e72. doi: 10.1016/j.bbmt.2018.12.067. Epub 2018 Dec 15.
7
Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.骨髓原始细胞小于5%的低危骨髓增生异常综合征的非清髓性预处理——一项可行性研究
Ann Hematol. 2016 Jun;95(7):1151-61. doi: 10.1007/s00277-016-2679-x. Epub 2016 Apr 22.
8
Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?异基因干细胞移植治疗骨髓增生异常综合征：移植前克隆负荷重要吗？
Curr Opin Hematol. 2016 Mar;23(2):167-74. doi: 10.1097/MOH.0000000000000217.
9
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.异基因造血干细胞移植治疗骨髓增生异常综合征和慢性粒-单核细胞白血病：国际专家小组的建议
Blood. 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17.
10
Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome.异基因造血干细胞移植治疗骨髓增生异常综合征。
Hematology Am Soc Hematol Educ Program. 2010;2010:325-9. doi: 10.1182/asheducation-2010.1.325.
引用本文的文献
1
Use of Hematopoietic Cell Transplant for Hematologic Cancers by Race, Ethnicity, and Age.种族、民族和年龄对血液系统恶性肿瘤患者造血干细胞移植的应用。
JAMA Netw Open. 2024 Sep 3;7(9):e2433145. doi: 10.1001/jamanetworkopen.2024.33145.
2
Transplantation and Cellular Therapy for Older Adults-The MSK Approach.老年人的移植和细胞治疗——MSK 方法。
Curr Hematol Malig Rep. 2024 Apr;19(2):82-91. doi: 10.1007/s11899-024-00725-y. Epub 2024 Feb 9.
3
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?我们如何将新证据更好地转化到造血细胞移植和细胞治疗的实践中？
Blood Rev. 2023 Jul;60:101079. doi: 10.1016/j.blre.2023.101079. Epub 2023 Apr 7.
4
Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).评估骨髓增生异常综合征（MDS）中部分血液学恢复（CRh）作为完全缓解（CR）的反应标准。
Blood Cancer J. 2022 Nov 15;12(11):153. doi: 10.1038/s41408-022-00748-9.
本文引用的文献
1
Under-use of Hypomethylating Agents in Patients With Higher-risk Myelodysplastic Syndrome in the United States: A Large Population-based Analysis.美国高危骨髓增生异常综合征患者中低甲基化药物的未充分使用：一项大型基于人群的分析。
Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):e206-e211. doi: 10.1016/j.clml.2020.10.013. Epub 2020 Oct 26.
2
Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.美国成人造血细胞移植的障碍：一项以年龄为重点的系统评价
Biol Blood Marrow Transplant. 2020 Dec;26(12):2335-2345. doi: 10.1016/j.bbmt.2020.09.013. Epub 2020 Sep 20.
3
Clinical Decision Making: Communicating Risk and Engaging Patients in Shared Decision Making.临床决策：沟通风险并让患者参与共同决策。
Ann Intern Med. 2020 May 19;172(10):688-692. doi: 10.7326/M19-3495. Epub 2020 Apr 21.
4
Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis.骨髓增生异常综合征中清髓性与减低强度造血细胞移植：系统评价与荟萃分析
Biol Blood Marrow Transplant. 2020 Jun;26(6):e138-e141. doi: 10.1016/j.bbmt.2020.03.003. Epub 2020 Mar 12.
5
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.有残留疾病基因组证据的急性髓细胞性白血病异体移植的条件强度的影响。
J Clin Oncol. 2020 Apr 20;38(12):1273-1283. doi: 10.1200/JCO.19.03011. Epub 2019 Dec 20.
6
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.骨髓增生异常综合征患者年龄组在移植中的比较：医疗保险覆盖范围与证据发展研究。
JAMA Oncol. 2020 Apr 1;6(4):486-493. doi: 10.1001/jamaoncol.2019.5140.
7
Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy.临床试验中少数族裔的招募：在免疫治疗时代，老问题有了新的紧迫性。
Am Soc Clin Oncol Educ Book. 2019 Jan;39:3-10. doi: 10.1200/EDBK_100021. Epub 2019 May 17.
8
Treatment of MDS.骨髓增生异常综合征的治疗。
Blood. 2019 Mar 7;133(10):1096-1107. doi: 10.1182/blood-2018-10-844696. Epub 2019 Jan 22.
9
Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States.美国常规临床护理中接受高风险骨髓增生异常综合征（HR-MDS）治疗患者的经济负担。
Pharmacoecon Open. 2019 Jun;3(2):237-245. doi: 10.1007/s41669-018-0100-5.
10
Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America.北美慢性移植物抗宿主病患者的就业、保险和财务经历。
Biol Blood Marrow Transplant. 2019 Mar;25(3):599-605. doi: 10.1016/j.bbmt.2018.09.040. Epub 2018 Oct 5.
Zotero 插件